CA1277595C - Method and composition for regulating serum calcium levels of mammals - Google Patents
Method and composition for regulating serum calcium levels of mammalsInfo
- Publication number
- CA1277595C CA1277595C CA000514753A CA514753A CA1277595C CA 1277595 C CA1277595 C CA 1277595C CA 000514753 A CA000514753 A CA 000514753A CA 514753 A CA514753 A CA 514753A CA 1277595 C CA1277595 C CA 1277595C
- Authority
- CA
- Canada
- Prior art keywords
- liposome
- hormone
- composition
- polypeptide hormone
- calcitonin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
Abstract
A METHOD AND COMPOSITION FOR REGULATING
SERUM CALCIUM LEVELS OF MAMMALS
Abstract of the Disclosure Method for regulating serum calcium levels in mammals by orally administering a composition which includes a polypeptide hormone such as parathyroid hormone (PTH) or calcitonin. The polypeptide hormone is protected from destruction in the digestive tract by encapsulation in liposomes. The liposome preferably includes a cationic amphiphilic agent so that the surface of the liposome has a net positive charge. Agents for enhancing the action of the liposome encapsulated hormones are also disclosed.
SERUM CALCIUM LEVELS OF MAMMALS
Abstract of the Disclosure Method for regulating serum calcium levels in mammals by orally administering a composition which includes a polypeptide hormone such as parathyroid hormone (PTH) or calcitonin. The polypeptide hormone is protected from destruction in the digestive tract by encapsulation in liposomes. The liposome preferably includes a cationic amphiphilic agent so that the surface of the liposome has a net positive charge. Agents for enhancing the action of the liposome encapsulated hormones are also disclosed.
Description
~ 77~i95 1 621~6-481 A METHOD AND COHPOSITION FOR REGULATING
SERUM CALCIUH L~VELS OF MAMMALS
Background of the Invention Calcium is the most abundant and one of the most important mlnerals in the human body. Calcium is also an important cation in a wide variety of biological functions such as clo~ting of blood, the maintenance of normal heart beat and the initiation of neuromuscular and metabolic activities. The skeletal system provides an important reservoir for blood calcium in these processes. More than 99 percent of the calcium in the body is present in the skeleton as hydroxyapatite. Various diseases and metabolic disorders can cause the level of ~erum calcium to lncrease or decrease and thus cause serious biochemical and clinical abnormalities.
Of the factors which control calcium and skeletal metabolism, two polypeptide hormones, parathyroid hormone and calcitonin, are considered to be the most important. Parathyroid hormone (PTH) is an 84-amino acid peptide that acts to raise blood calcium and increase bone resorption. Calcltonin is a 32-amino acid polypeptlde ~hat acts to decrease bone resorption and lower blood calcium. Calcitonin is produced in the thyroid gland and perhaps at extra thyroidal sites and parathyroid hormone is produced ln the parathyroid glands. The half llfe of calcitonin and of parathyroid hormone in the human body can be measured in minutes.
In general, the secretion of parathyroid hormone and calcitonin in the human body maintain normal mineral and skeletal metabolism. However, there are various dlsorders in which the -3L277S9~
SERUM CALCIUH L~VELS OF MAMMALS
Background of the Invention Calcium is the most abundant and one of the most important mlnerals in the human body. Calcium is also an important cation in a wide variety of biological functions such as clo~ting of blood, the maintenance of normal heart beat and the initiation of neuromuscular and metabolic activities. The skeletal system provides an important reservoir for blood calcium in these processes. More than 99 percent of the calcium in the body is present in the skeleton as hydroxyapatite. Various diseases and metabolic disorders can cause the level of ~erum calcium to lncrease or decrease and thus cause serious biochemical and clinical abnormalities.
Of the factors which control calcium and skeletal metabolism, two polypeptide hormones, parathyroid hormone and calcitonin, are considered to be the most important. Parathyroid hormone (PTH) is an 84-amino acid peptide that acts to raise blood calcium and increase bone resorption. Calcltonin is a 32-amino acid polypeptlde ~hat acts to decrease bone resorption and lower blood calcium. Calcitonin is produced in the thyroid gland and perhaps at extra thyroidal sites and parathyroid hormone is produced ln the parathyroid glands. The half llfe of calcitonin and of parathyroid hormone in the human body can be measured in minutes.
In general, the secretion of parathyroid hormone and calcitonin in the human body maintain normal mineral and skeletal metabolism. However, there are various dlsorders in which the -3L277S9~
productlon of these two peptides is deficient. Furthermore, there are diseases in which the administration of these two pep~ides alone or in combination to regulate blood calcium levels may be therapeutically important. Such diseases include but are not restricted to hypoparathyroidism, renal osteodystrophy, Paget's disease, malignancy with hypercalcemia and osteoporosis.
In order to treat and control the elevated or subnormal blood calcium levels due to abnormal calclum and skeletal metabolism, it has generally been the practice to treat individuals with either parathyroid hormone or calcitonin by lnjection using a syringe and needle. Furthermore, due to the relatively short half life of parathyroid hormone and calcitonin in the human body, it is necessary to continually administer the hormone by injection. Such a continuous schedule of hormone injections is burdensome, inconvenient and palnful.
One way to improve the administra~lon of these peptides is to increase the half life of the PTH and calcltonin which is in~ected into the lndividual. In ~he past, we have increased the tlme effectiveness of injected calcitonin by lncorporating the calcltonin into lipoæomes prior to injection into the body.
Liposomes, which are also known as lipid vesicles, are composed of a spherical phospholipid bilayer encloslng an aqueous compartment. Due to the semi-permeable nature of tha llpid bilayer, the liposomes have been found useful as carriers for various biologically active agents since the lipid bilayer protects the entrapped agent from unwanted metabolic conversions.
The .
.
~277~;9~i use of liposome encapsulated calcitonin has been found effective in increasing the half life of calcitonin injections in the body to thereby decrease the frequency of injections required to produce and maintain the hypocalcemic effect of the hormone.
It would be desirable to provide PTH and calcitonin preparations which can be administered orally to the patient. In the past, attempts have been made to administer PTH and calcitonin by mouth. However, these methods have not resulted in orally effective prepara-tions. Accordingly, it would be desirable to provide PTH
and calcitonin preparations which produce their biolo-gical effect when taken orally.
Summary of the Invention -In accordance with the present invention a method and composition are provided for regulating and con-trolling calcium and skeletal metabolism by the oral administration of the polypeptide hormones, calcitonin and parathyroid hormone. The present invention is based upon the discovery that parathyroid hormone and calcitonin, which are encapsulated in phospholipid liposomes, can be taken orally to achieve their bio-logical effect. It appears that the liposome protects the polypeptide hormone from destruction by digestive enzymes pres~ent in the small bowel and facilitates absorption of the polypeptide hormones.
As one feature of the present invention, the liposome or vesicle may include a sufficient amount of an amphiphilic agent to provide the surface of the liposome with a net positive charge in order to optimize the oral effectiveness of the preparations.
As another feature of the present invention, it was found that certain additives were effective in improving the action of liposome encapsulated polypeptide hormones when orally administered. These enhancement agents i95 include aspirin derivatives such as sodium salicylate, sodium salicylamide acetylysalicylate, methylsalicylate, and the enzyme inhibitor aprotonin.
Although the exact mechanism by which the liposomes protect the polypeptide hormones from destruction in the small intestine is not known, it is believed that the liposome wall (lipid bilayer) protects the polypeptide hormone from destruction by digestive enzymes present in the small bowel and facilitate its absorption into the blood. The liposome entrapped calcitonin and parathyroid hormones in accordance with the present invention have been shown to affect the serum calcium levels in animals while the free hormone administered orally has no effect.
The present invention therefore provides a new and unique ~5 method for regulating blood calcium levels by oral administration of liposomes containing either calcitonin or parathyroid hormone.
The above described and other features and atten-dant advantages of the present invention will become apparent as the invention becomes better understood by reference to the following detailed description.
Detailed Descxiption of the Invention The present invention involves entrapping poly-peptide hormones such as parathyoid hormone (PTH) andcalcitonin in phospholipid liposomes so that the polypeptide hormone may be introduced orally (including nasal administration) into animals without being destroyed in the digestive tract. The present invention is useful in treating any number of diseases related to abnormal skeletal metabolism such as, but not limited to, hypercalcemia, Paget's diseases, renal osteodystrophy, and osteopososis.
Any of the well known procedures and techniques for preparing liposomes may be utilized in accordance with the present invention so long as encapsulation of the .
~75~5 polypeptide hormone is provided. Basically, these procedures generally involve the production of a thin phospholipid film followed by agitation with an aqueous, buffered solution containing the hormones to give a dispersion of closed vesicles.
The polypeptide hormone is incorporated into the liposome as follows: the phospholipid components are dissolved in an organic solvent such as chloroform. The solvent is then removed to produce a lipid film. A
buffer solution containing the polypeptide hormone is then added and mixed to form a suspension of the phospholipid film and polypeptide hormone. The suspen-sion is then sonicated to form the liposome-entrapped polypeptide hormone. The suspension is then centrifuged at 120,000 times g for 16 hours to obtain a pellet consisting of liposome-entrapped hormone while the supernatant contains the unentrapped hormone. The liposomes in the pellet are then taken up in a small amount of buffer and subsequently used to influence calcium homestasis by oral administration.
The liposomes used in the present invention may be prepared from natural or synthetic phospholipids such as, but not limited to, phosphatidylcholine isolated from egg yolk, dimristoylphosphatidylcholine and dipalmitoylphos-phatidylcholine.
In addition to the phospholipid component of theliposome, a sufficient amount of an amphiphilic agent is preferably included to provide the surface of the liposome with a net positive charge. It has been determined that the net positive charge on the liposome surface enhances the oral effectiveness of the prepara-tion. Suitable amphiphiles which can be used include alkyl amines having the general formula CnH2n+lNH2 where n is 12 to 20. Stearylamine is preferred alkyl amine.
The amount of amphiphile added should be sufficient to provide a net positive charge on the liposome surface.
, ~9~
The molar percentage of alkylamine may vary widely from 0.5% up to about 99.5~. The preferred molar percentage of alkylamine is between about 1% and 20%.
Calcitonin of both natural and synthetic origin may be used for incorporation into the liposomes.
Calcitonin is readily available polypeptide hormone which can be obtained from any number of suitable commercial outlets such as Peninsula Laboratories, San Carlos, CA.
Calcitonin is a polypeptide hormone secreted by the parafollicular cells of the thyroid gland in mammals and by the ultimobranchial gland of birds and flsh.
Calcitonin includes 32 amino acids with a seven membered disulfide ring at the amino terminal end and a proline amide at the carboxy terminal end. The amino acid structure of the different species of calcitonin differ.
All of the calcitonin species may be used in accordance with the present invention including bovine, porcine, ovine, salmon, eel, rat, and human. Human, salmon, and eel forms of the hormone are preferred because of their origin-and biological potency. In addition, derivatives of each species of calcitonin such as aminosuberic substituted forms and other derivatives not occurring in nature are also of interest for use in the present application.
Calcitonin-salmon is of salmon origin or synthetic origin with both forms having 32 amino acids arranged in the same linear sequence. Salmon calcitonin appears to have actions essentially identical to calcitonins of mammalian origin, but with greater potency and longer duration of action. Any of the calcitonins which have been shown to be effective when administered by injection will also be effec~ive when encapsulated and administered orally in accordance with our invention.
Parathyroid hormone is also available from com-mercial outlets such as Peninsula Laboratories, San Carlos, CA. Parathyroid hormone having the 1-34 amino acid fragment is preferred. Parathyroid hormone is a peptide with 84 amino acids. The amino acid sequence is different among the human, bovine and murine forms of the peptide. Although all species of parathyroid hormone may be used, a fragment of the human and bovine hormones at their amino terminus containing approximately the first 34 amino acids and commonly referred to as bovine para-thyroid hormone 1-34 (bPTH 1-34) and human parathyroid hormone 1-34 (hPTH 1-34) are preferred because of their biological potencies. Parathyroid hormone having fragments with more or less amino acids can be utilized, however parathyroid hormone having in the neighborhood of 80 to 85 amino acids is very expensive and may be no more effective as parathyroid hormone fragments having fewer amino acids. In general, any PTH fragments which have been shown to be effective when administered by injection should also be effective when encapsulated and admin-istered orally in accordance with our invention.
The encapsulated parathyroid hormone or calcitonin is preferably administered orally as a buffered aqueous solution. Any pharmaceutically acceptable aqueous buffer may be utlized so long as it does not destroy the activity of the encapsulated polypeptide hormones and is suitable for oral administration. A preferred aqueous buffer is 20 mM NaCl containing 5 mM Tris-HCl which may have a pH of between 4.0 and 8Ø
Examples of practice are as follows:
Purified salmon and human calcitonin or human parathyroid hormone (1-34 amino acid fragment) were incorporated into liposomes consisting of natural or synthetic phospholipids and positively-charged amine-containing amphiphile. Liposomes containing the en-trapped hormones were isolated by centrifugation, resuspended in buffer and administered by stomach tube to fasted normal rats (calcitonin) or fasted parathyroidec-tomized rats (parathyroid hormone). The serum calcium ~277~
was determined at various time intervals in treated and untreated animals to assess the effect of the respective preparations.
~xample_l 450 micromoles of egg phosphatidylcholine (ePC) and 50 micromoles of stearylamine (SA) were dissolved in 2 to 3 ml of anhydrous chloroform placed in a 30 ml glass stopper tube and the solvent was removed in _vacuo. To the thin film of lipid remaining on the wall of the tube was added 5.0 ml of buffer ~20 mM NaCl containing 5 mM
Tris, pH 7.4) containing 1 mg human PTH (hPTH 1-343 and 1 x 10 CPM of I12 -human PTH tracer (hPTH 1-34). The buffer was mixed at room temperature for 5 minutes using a vortex mixer.
After vortexing the mixture was sonicated for 3 minutes at room temperature using the cuphorn of a Heat Systems Ultrasonics sonicator at maximal output. The mixture was transferred to a polycarbonate tube and centrifuged at 4C using 50 Ti rotor and L265B ultra-centrifuge (Beckmann Instruments) for 16 hours at 120,000 xg. The pellet, consisting of liposomes containing human PTH (1-34), was resuspended in 1.0 ml of of buffer (20 mM
NaCl containing 5 mM Tris, pH 7.4) containing 2% cysteine as a preserval:ive.
Oral administration of varying amounts of the egg phosphatidylcholine/stearylamine liposomes containing human PTH to parathyroidectomized rats had the effect on the serum calcium after 2 hours as shown in Table 1:
Table 1 Changes in Dose serum Ca2 mg/dl None -0.13 g PTH -0.03 g PTH +0.2~3 g PTH +0.92 ' ' -: .
.~ ,,: .
~ g5 The effect of oral free human PTH was compared to that of liposome-entrapped PTH (egg PC/stearylamine, 9/1) after 2 hr. The results are shown in Table 2.
Table 2 Preparation Chan~ n Serum Ca2 mg/dl .
Free PTH, 40 g +0.08 0.25 (3) Liposomal PTH, 40 g +0.37 0.02 (3) (3) test run in triplicate, mean + Std. error of mean Other liposome preparations and other control studies were done with the results being shown in Table 3. The results show the effect on serum calcium 2 hours after oral a &inistration to rats.
Table 3 Preparation Change in serum Ca2 mg/dl Buffer alone -0.10 Buffer + 2% cysteine -1.04 ePC/SA (9/1)-empty liposome -0.88 Empty liposome + free PTH, 40 g -0.6 Free PTH, 40 g _0.05 Buffer + 2~ Cysteine +0.27 +0.07 (3) ePC/SA (9/1) 40 g PTH +0.98 +0.24 (3) ePC/cholesterol/stearylamine (7/2/1) 40 g PTH +0.54 +0.24 (3) ePC/Cholesterol/dietylphosphate (7/2/1) 40 g PTH +0.56 +0.03 (3) ePC, 40 g PTH -0.07 (3) test run in triplicate, mean + Std. error of mean The above experiments demonstrates that orally 1~27~i95 administered ePC/stearylamine liposomes containing human PTH (hPTH 1-34) raise the serum calcium of rats while an equivalent dose of free PTH, buffer, PTH plus empty liposomes has no effect.
Example 2 In this example, liposomes were prepared as in Example l except that the buffer contained l mg calcitonin (CT) instead of human PTH.
Liposomes consisting of e~g phosphatidylcholine and stearylamine (8:2) and containing 28.4 units of salmon calcitonin (sCT) were administered by the oral route to fasted normal rats. Serum calcium was determined after l hour with the results being shown in Table 4.
Table 4 Change in Treatment Serum Ca2+ mg/dl None Free sCT 0 Liposomal sCT (egg PC/SA, 8:2) -l.0 Lipo sCT + Aprotonin, 2000 i.u. -2.2 Lipo sCT + 40 mg sodium salicylate -2.4 Lipo sCT 39 mg salicylamide -2.5 Lipo sCT + 40 mg acetylsalicylate -2.8 Lipo sCT + 200 l methylsalicylate -2.9 As is apparent from Table 4l oral administration of liposome encapsulated calcitonin lowers serum calcium while the free hormone given in the same way has no effect. In addition, aspirin derivatives and aprotonin enhance the effect of liposo~al CT. Suitable aspirin derivatives include sodium salicylate sodium salicylamide, acetylsalicylate and methylsalicylate.
Aprotonin is an enzyme inhibitor marketed under the tradename Traysylol and identified in U.S. Pat. No.
2,890,986.
.
~27~S~;
Additional control experiments were carried out to prove that liposomal entrapment is responsible for the oral effect of sCT. The results are shown in Table 5.
Table 5 Change in Serum reatment Serum Ca, mg/dl Ca, mg/dl none 9.2 free sCT* 8.9 -0.3 free sCT* + 20 mg aspirin 8.4 -0.8 liposomal sCT**
+ 20 mg aspirin 6.7 -2.5 * sCT dose, 19.2V per rat by oral administration ** egg PC/stearylamine, 8/2 The results in Table 5 demonstrate that aspirin en-hances slightly the effect of free CT. Maximal responses 2~ are seen with liposomal entrapment of sCT in ePC/stearylamine vesicles (8:2).
As is apparent, examples (1) and (2) demonstrate that calcitonin and parathyroid hormone can be entrapped in liposomes and then administered orally to achieve their biological effect. These preparations could be useful in the treatment of a large number of human diseases of calcium and skeletal metabolism. The particular dosages of PTH and calcitonin required to achieve desired serum calcium regulations will vary depending upon actual calcium level in each individual and the degree of disease or metabolic disorder.
Having thus described exemplary embodiments of the present invention, it should be noted by those skilled in the art that the within disclosures are exemplary only and that various other a~ternatives, adaptations and modifications may be made within the scope of the present invention. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is limited only by the following claims.
.
: ':
- .
.
In order to treat and control the elevated or subnormal blood calcium levels due to abnormal calclum and skeletal metabolism, it has generally been the practice to treat individuals with either parathyroid hormone or calcitonin by lnjection using a syringe and needle. Furthermore, due to the relatively short half life of parathyroid hormone and calcitonin in the human body, it is necessary to continually administer the hormone by injection. Such a continuous schedule of hormone injections is burdensome, inconvenient and palnful.
One way to improve the administra~lon of these peptides is to increase the half life of the PTH and calcltonin which is in~ected into the lndividual. In ~he past, we have increased the tlme effectiveness of injected calcitonin by lncorporating the calcltonin into lipoæomes prior to injection into the body.
Liposomes, which are also known as lipid vesicles, are composed of a spherical phospholipid bilayer encloslng an aqueous compartment. Due to the semi-permeable nature of tha llpid bilayer, the liposomes have been found useful as carriers for various biologically active agents since the lipid bilayer protects the entrapped agent from unwanted metabolic conversions.
The .
.
~277~;9~i use of liposome encapsulated calcitonin has been found effective in increasing the half life of calcitonin injections in the body to thereby decrease the frequency of injections required to produce and maintain the hypocalcemic effect of the hormone.
It would be desirable to provide PTH and calcitonin preparations which can be administered orally to the patient. In the past, attempts have been made to administer PTH and calcitonin by mouth. However, these methods have not resulted in orally effective prepara-tions. Accordingly, it would be desirable to provide PTH
and calcitonin preparations which produce their biolo-gical effect when taken orally.
Summary of the Invention -In accordance with the present invention a method and composition are provided for regulating and con-trolling calcium and skeletal metabolism by the oral administration of the polypeptide hormones, calcitonin and parathyroid hormone. The present invention is based upon the discovery that parathyroid hormone and calcitonin, which are encapsulated in phospholipid liposomes, can be taken orally to achieve their bio-logical effect. It appears that the liposome protects the polypeptide hormone from destruction by digestive enzymes pres~ent in the small bowel and facilitates absorption of the polypeptide hormones.
As one feature of the present invention, the liposome or vesicle may include a sufficient amount of an amphiphilic agent to provide the surface of the liposome with a net positive charge in order to optimize the oral effectiveness of the preparations.
As another feature of the present invention, it was found that certain additives were effective in improving the action of liposome encapsulated polypeptide hormones when orally administered. These enhancement agents i95 include aspirin derivatives such as sodium salicylate, sodium salicylamide acetylysalicylate, methylsalicylate, and the enzyme inhibitor aprotonin.
Although the exact mechanism by which the liposomes protect the polypeptide hormones from destruction in the small intestine is not known, it is believed that the liposome wall (lipid bilayer) protects the polypeptide hormone from destruction by digestive enzymes present in the small bowel and facilitate its absorption into the blood. The liposome entrapped calcitonin and parathyroid hormones in accordance with the present invention have been shown to affect the serum calcium levels in animals while the free hormone administered orally has no effect.
The present invention therefore provides a new and unique ~5 method for regulating blood calcium levels by oral administration of liposomes containing either calcitonin or parathyroid hormone.
The above described and other features and atten-dant advantages of the present invention will become apparent as the invention becomes better understood by reference to the following detailed description.
Detailed Descxiption of the Invention The present invention involves entrapping poly-peptide hormones such as parathyoid hormone (PTH) andcalcitonin in phospholipid liposomes so that the polypeptide hormone may be introduced orally (including nasal administration) into animals without being destroyed in the digestive tract. The present invention is useful in treating any number of diseases related to abnormal skeletal metabolism such as, but not limited to, hypercalcemia, Paget's diseases, renal osteodystrophy, and osteopososis.
Any of the well known procedures and techniques for preparing liposomes may be utilized in accordance with the present invention so long as encapsulation of the .
~75~5 polypeptide hormone is provided. Basically, these procedures generally involve the production of a thin phospholipid film followed by agitation with an aqueous, buffered solution containing the hormones to give a dispersion of closed vesicles.
The polypeptide hormone is incorporated into the liposome as follows: the phospholipid components are dissolved in an organic solvent such as chloroform. The solvent is then removed to produce a lipid film. A
buffer solution containing the polypeptide hormone is then added and mixed to form a suspension of the phospholipid film and polypeptide hormone. The suspen-sion is then sonicated to form the liposome-entrapped polypeptide hormone. The suspension is then centrifuged at 120,000 times g for 16 hours to obtain a pellet consisting of liposome-entrapped hormone while the supernatant contains the unentrapped hormone. The liposomes in the pellet are then taken up in a small amount of buffer and subsequently used to influence calcium homestasis by oral administration.
The liposomes used in the present invention may be prepared from natural or synthetic phospholipids such as, but not limited to, phosphatidylcholine isolated from egg yolk, dimristoylphosphatidylcholine and dipalmitoylphos-phatidylcholine.
In addition to the phospholipid component of theliposome, a sufficient amount of an amphiphilic agent is preferably included to provide the surface of the liposome with a net positive charge. It has been determined that the net positive charge on the liposome surface enhances the oral effectiveness of the prepara-tion. Suitable amphiphiles which can be used include alkyl amines having the general formula CnH2n+lNH2 where n is 12 to 20. Stearylamine is preferred alkyl amine.
The amount of amphiphile added should be sufficient to provide a net positive charge on the liposome surface.
, ~9~
The molar percentage of alkylamine may vary widely from 0.5% up to about 99.5~. The preferred molar percentage of alkylamine is between about 1% and 20%.
Calcitonin of both natural and synthetic origin may be used for incorporation into the liposomes.
Calcitonin is readily available polypeptide hormone which can be obtained from any number of suitable commercial outlets such as Peninsula Laboratories, San Carlos, CA.
Calcitonin is a polypeptide hormone secreted by the parafollicular cells of the thyroid gland in mammals and by the ultimobranchial gland of birds and flsh.
Calcitonin includes 32 amino acids with a seven membered disulfide ring at the amino terminal end and a proline amide at the carboxy terminal end. The amino acid structure of the different species of calcitonin differ.
All of the calcitonin species may be used in accordance with the present invention including bovine, porcine, ovine, salmon, eel, rat, and human. Human, salmon, and eel forms of the hormone are preferred because of their origin-and biological potency. In addition, derivatives of each species of calcitonin such as aminosuberic substituted forms and other derivatives not occurring in nature are also of interest for use in the present application.
Calcitonin-salmon is of salmon origin or synthetic origin with both forms having 32 amino acids arranged in the same linear sequence. Salmon calcitonin appears to have actions essentially identical to calcitonins of mammalian origin, but with greater potency and longer duration of action. Any of the calcitonins which have been shown to be effective when administered by injection will also be effec~ive when encapsulated and administered orally in accordance with our invention.
Parathyroid hormone is also available from com-mercial outlets such as Peninsula Laboratories, San Carlos, CA. Parathyroid hormone having the 1-34 amino acid fragment is preferred. Parathyroid hormone is a peptide with 84 amino acids. The amino acid sequence is different among the human, bovine and murine forms of the peptide. Although all species of parathyroid hormone may be used, a fragment of the human and bovine hormones at their amino terminus containing approximately the first 34 amino acids and commonly referred to as bovine para-thyroid hormone 1-34 (bPTH 1-34) and human parathyroid hormone 1-34 (hPTH 1-34) are preferred because of their biological potencies. Parathyroid hormone having fragments with more or less amino acids can be utilized, however parathyroid hormone having in the neighborhood of 80 to 85 amino acids is very expensive and may be no more effective as parathyroid hormone fragments having fewer amino acids. In general, any PTH fragments which have been shown to be effective when administered by injection should also be effective when encapsulated and admin-istered orally in accordance with our invention.
The encapsulated parathyroid hormone or calcitonin is preferably administered orally as a buffered aqueous solution. Any pharmaceutically acceptable aqueous buffer may be utlized so long as it does not destroy the activity of the encapsulated polypeptide hormones and is suitable for oral administration. A preferred aqueous buffer is 20 mM NaCl containing 5 mM Tris-HCl which may have a pH of between 4.0 and 8Ø
Examples of practice are as follows:
Purified salmon and human calcitonin or human parathyroid hormone (1-34 amino acid fragment) were incorporated into liposomes consisting of natural or synthetic phospholipids and positively-charged amine-containing amphiphile. Liposomes containing the en-trapped hormones were isolated by centrifugation, resuspended in buffer and administered by stomach tube to fasted normal rats (calcitonin) or fasted parathyroidec-tomized rats (parathyroid hormone). The serum calcium ~277~
was determined at various time intervals in treated and untreated animals to assess the effect of the respective preparations.
~xample_l 450 micromoles of egg phosphatidylcholine (ePC) and 50 micromoles of stearylamine (SA) were dissolved in 2 to 3 ml of anhydrous chloroform placed in a 30 ml glass stopper tube and the solvent was removed in _vacuo. To the thin film of lipid remaining on the wall of the tube was added 5.0 ml of buffer ~20 mM NaCl containing 5 mM
Tris, pH 7.4) containing 1 mg human PTH (hPTH 1-343 and 1 x 10 CPM of I12 -human PTH tracer (hPTH 1-34). The buffer was mixed at room temperature for 5 minutes using a vortex mixer.
After vortexing the mixture was sonicated for 3 minutes at room temperature using the cuphorn of a Heat Systems Ultrasonics sonicator at maximal output. The mixture was transferred to a polycarbonate tube and centrifuged at 4C using 50 Ti rotor and L265B ultra-centrifuge (Beckmann Instruments) for 16 hours at 120,000 xg. The pellet, consisting of liposomes containing human PTH (1-34), was resuspended in 1.0 ml of of buffer (20 mM
NaCl containing 5 mM Tris, pH 7.4) containing 2% cysteine as a preserval:ive.
Oral administration of varying amounts of the egg phosphatidylcholine/stearylamine liposomes containing human PTH to parathyroidectomized rats had the effect on the serum calcium after 2 hours as shown in Table 1:
Table 1 Changes in Dose serum Ca2 mg/dl None -0.13 g PTH -0.03 g PTH +0.2~3 g PTH +0.92 ' ' -: .
.~ ,,: .
~ g5 The effect of oral free human PTH was compared to that of liposome-entrapped PTH (egg PC/stearylamine, 9/1) after 2 hr. The results are shown in Table 2.
Table 2 Preparation Chan~ n Serum Ca2 mg/dl .
Free PTH, 40 g +0.08 0.25 (3) Liposomal PTH, 40 g +0.37 0.02 (3) (3) test run in triplicate, mean + Std. error of mean Other liposome preparations and other control studies were done with the results being shown in Table 3. The results show the effect on serum calcium 2 hours after oral a &inistration to rats.
Table 3 Preparation Change in serum Ca2 mg/dl Buffer alone -0.10 Buffer + 2% cysteine -1.04 ePC/SA (9/1)-empty liposome -0.88 Empty liposome + free PTH, 40 g -0.6 Free PTH, 40 g _0.05 Buffer + 2~ Cysteine +0.27 +0.07 (3) ePC/SA (9/1) 40 g PTH +0.98 +0.24 (3) ePC/cholesterol/stearylamine (7/2/1) 40 g PTH +0.54 +0.24 (3) ePC/Cholesterol/dietylphosphate (7/2/1) 40 g PTH +0.56 +0.03 (3) ePC, 40 g PTH -0.07 (3) test run in triplicate, mean + Std. error of mean The above experiments demonstrates that orally 1~27~i95 administered ePC/stearylamine liposomes containing human PTH (hPTH 1-34) raise the serum calcium of rats while an equivalent dose of free PTH, buffer, PTH plus empty liposomes has no effect.
Example 2 In this example, liposomes were prepared as in Example l except that the buffer contained l mg calcitonin (CT) instead of human PTH.
Liposomes consisting of e~g phosphatidylcholine and stearylamine (8:2) and containing 28.4 units of salmon calcitonin (sCT) were administered by the oral route to fasted normal rats. Serum calcium was determined after l hour with the results being shown in Table 4.
Table 4 Change in Treatment Serum Ca2+ mg/dl None Free sCT 0 Liposomal sCT (egg PC/SA, 8:2) -l.0 Lipo sCT + Aprotonin, 2000 i.u. -2.2 Lipo sCT + 40 mg sodium salicylate -2.4 Lipo sCT 39 mg salicylamide -2.5 Lipo sCT + 40 mg acetylsalicylate -2.8 Lipo sCT + 200 l methylsalicylate -2.9 As is apparent from Table 4l oral administration of liposome encapsulated calcitonin lowers serum calcium while the free hormone given in the same way has no effect. In addition, aspirin derivatives and aprotonin enhance the effect of liposo~al CT. Suitable aspirin derivatives include sodium salicylate sodium salicylamide, acetylsalicylate and methylsalicylate.
Aprotonin is an enzyme inhibitor marketed under the tradename Traysylol and identified in U.S. Pat. No.
2,890,986.
.
~27~S~;
Additional control experiments were carried out to prove that liposomal entrapment is responsible for the oral effect of sCT. The results are shown in Table 5.
Table 5 Change in Serum reatment Serum Ca, mg/dl Ca, mg/dl none 9.2 free sCT* 8.9 -0.3 free sCT* + 20 mg aspirin 8.4 -0.8 liposomal sCT**
+ 20 mg aspirin 6.7 -2.5 * sCT dose, 19.2V per rat by oral administration ** egg PC/stearylamine, 8/2 The results in Table 5 demonstrate that aspirin en-hances slightly the effect of free CT. Maximal responses 2~ are seen with liposomal entrapment of sCT in ePC/stearylamine vesicles (8:2).
As is apparent, examples (1) and (2) demonstrate that calcitonin and parathyroid hormone can be entrapped in liposomes and then administered orally to achieve their biological effect. These preparations could be useful in the treatment of a large number of human diseases of calcium and skeletal metabolism. The particular dosages of PTH and calcitonin required to achieve desired serum calcium regulations will vary depending upon actual calcium level in each individual and the degree of disease or metabolic disorder.
Having thus described exemplary embodiments of the present invention, it should be noted by those skilled in the art that the within disclosures are exemplary only and that various other a~ternatives, adaptations and modifications may be made within the scope of the present invention. Accordingly, the present invention is not limited to the specific embodiments as illustrated herein, but is limited only by the following claims.
.
: ':
- .
.
Claims (22)
1. The use for regulating blood calcium levels in mammals of a blood calcium-regulating effective amount of a composition consisting essentially of an aqueous solution of a polypeptide hormone selected from the group consisting of parathyroid hormone and calcitonin, said polypeptide hormone being encapsulated in a liposome.
2. A use according to claim 1 wherein said polypeptide hormone is parathyroid hormone.
3. A use according to claim 2 wherein said polypeptide hormone is the hPTH 1-34 fragment of parathyroid hormone.
4. A use according to claim 1 wherein said polypeptide hormone is calcitonin.
5. A use according to claim 1 wherein said liposome contains a sufficient amount of alkylamine having the general formula CnH2n+1NH2, where n is 12 to 20 to provide the surface of said liposome with a net positive charge.
6. A use according to claim 5 wherein said alkylamine is stearylamine.
7. A use according to claim 1 wherein said composition further includes salicylate, salicylamide, acetylsalicylate or methylsalicylate to improve the blood calcium-regulating action of said polypeptide hormone encapsulated in said liposome.
8. A use according to claim 2 wherein said composition further includes an effective amount of cysteine as a preservative for the parathyroid hormone.
9. A use according to claim 1 wherein said liposome is made from phospholipids selected from the group consisting of phosphatidylcholine, dimristoyl-phosphatidylcholine and dipalmitoylphosphatidylcholine.
10. A composition for oral administration in mammals to regulate blood calcium levels, said composition consisting essentially of a blood calcium-regulating effective amount of a polypeptide hormone selected from the group consisting of parathyroid hormone and calcitonin, said polypeptide hormone being encapsu-lated in a liposome, said liposome including a sufficient amount of an alkylamine having the general formula CnH2n+1NH2 where n is 12 to 20 to provide the surface of said liposome with a net positive charge.
11. A composition according to claim 10 wherein said polypeptide hormone is parathyroid hormone.
12. A composition according to claim 10 wherein said polypeptide hormone is calcitonin.
13. A composition according to claim 10 wherein said polypeptide hormone includes the hPTH 1-34 amino acid fragment of parathyroid hormone.
14. A composition according to claim 10 wherein said alkylamine is stearylamine.
15. A composition according to claim 10 wherein said composition further includes salicylate, salicylamide, acetylsalicylate or methylsalicylate to improve the blood calcium-regulating action of said polypeptide hormone encapsulated in said liposome.
16. A composition according to claim 10 further including an effective amount of cysteine as a preservative for the parathyroid hormone.
17. A composition according to claim 10 including a pharmaceutically acceptable aqueous buffer solution having a pH of between about 4.0 and 8Ø
18. A composition according to claim 10 wherein said liposome is made from phospholipids selected from the group consisting of phosphatidylcholine, dimristoy-lyphosphatidylcholine and dipalmitoylphosphatidylcholine.
19. A use according to claim 1 wherein said composition includes aprotonin to improve the blood calcium-regulating action of said polypeptide hormone encapsulated in said liposome.
20. A composition according to claim 10 further including aprotonin to improve the blood calcium-regulating action of said polypeptide hormone encap-sulated in said liposome.
21. A use according to claim 4 wherein said polypeptide hormone is salmon calcitonin.
22. A composition according to claim 12 wherein said polypeptide hormone is salmon calcitonin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/761,751 US4692433A (en) | 1983-10-12 | 1985-08-01 | Method and composition for regulating serum calcium levels of mammals |
| US761,751 | 1985-08-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1277595C true CA1277595C (en) | 1990-12-11 |
Family
ID=25063174
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000514753A Expired - Fee Related CA1277595C (en) | 1985-08-01 | 1986-07-28 | Method and composition for regulating serum calcium levels of mammals |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4692433A (en) |
| EP (1) | EP0233901B1 (en) |
| JP (1) | JPS63500378A (en) |
| AT (1) | ATE86102T1 (en) |
| AU (1) | AU6148186A (en) |
| CA (1) | CA1277595C (en) |
| DE (1) | DE3687899T2 (en) |
| IL (1) | IL79547A0 (en) |
| WO (1) | WO1987000750A1 (en) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
| US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| US4917951A (en) * | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
| US4911928A (en) * | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
| US5234767A (en) * | 1987-03-13 | 1993-08-10 | Micro-Pak, Inc. | Hybrid paucilamellar lipid vesicles |
| US5628936A (en) * | 1987-03-13 | 1997-05-13 | Micro-Pak, Inc. | Hybrid paucilamellar lipid vesicles |
| US4855090A (en) * | 1987-03-13 | 1989-08-08 | Micro-Pak, Inc. | Method of producing high aqueous volume multilamellar vesicles |
| US4942038A (en) * | 1987-03-13 | 1990-07-17 | Micro Vesicular Systems, Inc. | Encapsulated humectant |
| US5023086A (en) * | 1987-03-13 | 1991-06-11 | Micro-Pak, Inc. | Encapsulated ionophore growth factors |
| US5000960A (en) * | 1987-03-13 | 1991-03-19 | Micro-Pak, Inc. | Protein coupling to lipid vesicles |
| US5938654A (en) * | 1987-06-25 | 1999-08-17 | Alza Corporation | Osmotic device for delayed delivery of agent |
| US4853228A (en) * | 1987-07-28 | 1989-08-01 | Micro-Pak, Inc. | Method of manufacturing unilamellar lipid vesicles |
| US5019392A (en) * | 1988-03-03 | 1991-05-28 | Micro-Pak, Inc. | Encapsulation of parasiticides |
| US5104736A (en) * | 1988-03-03 | 1992-04-14 | Micro-Pak, Inc. | Reinforced paucilamellar lipid vesicles |
| US5019174A (en) * | 1988-03-03 | 1991-05-28 | Micro Vesicular Systems, Inc. | Removing oil from surfaces with liposomal cleaner |
| US5160669A (en) * | 1988-03-03 | 1992-11-03 | Micro Vesicular Systems, Inc. | Method of making oil filled paucilamellar lipid vesicles |
| US5817638A (en) * | 1988-07-07 | 1998-10-06 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
| US6252060B1 (en) | 1988-07-07 | 2001-06-26 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
| US6599887B2 (en) | 1988-07-07 | 2003-07-29 | Chimerix, Inc. | Methods of treating viral infections using antiviral liponucleotides |
| DE3886775T2 (en) * | 1988-08-22 | 1994-04-14 | Technology Unlimited Inc | DENTAL TREATMENT THROUGH VESICLE RELEASE. |
| US4942036A (en) * | 1988-08-25 | 1990-07-17 | Blair Geho W | Therapy by vesicle delivery to the hydroxyapatite of bone |
| US5026825A (en) * | 1988-09-08 | 1991-06-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Intranasal calcitonin formulations |
| JPH0395118A (en) * | 1989-09-07 | 1991-04-19 | Green Cross Corp:The | Prostaglandin-containing liposome preparation |
| AU6428890A (en) * | 1989-09-12 | 1991-04-18 | Regents Of The University Of California, The | Therapeutic peptides and proteins |
| US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
| US5714167A (en) * | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5578323A (en) | 1992-06-15 | 1996-11-26 | Emisphere Technologies, Inc. | Proteinoid carriers and methods for preparation and use thereof |
| US5693338A (en) * | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
| US6221367B1 (en) | 1992-06-15 | 2001-04-24 | Emisphere Technologies, Inc. | Active agent transport systems |
| US6099856A (en) * | 1992-06-15 | 2000-08-08 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5443459A (en) * | 1991-01-30 | 1995-08-22 | Alza Corporation | Osmotic device for delayed delivery of agent |
| US5688761A (en) * | 1991-04-19 | 1997-11-18 | Lds Technologies, Inc. | Convertible microemulsion formulations |
| US5683714A (en) * | 1991-04-19 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Liposomal cyclosporin pharmaceutical formulation |
| AU668509B2 (en) * | 1991-04-19 | 1996-05-09 | Affinity Biotech, Inc. | Convertible microemulsion formulations |
| US6916489B2 (en) * | 1992-06-15 | 2005-07-12 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5869305A (en) * | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| US6461643B2 (en) | 1993-04-22 | 2002-10-08 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US20010003001A1 (en) | 1993-04-22 | 2001-06-07 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5459126A (en) * | 1993-05-21 | 1995-10-17 | California Institute Of Technology | Method for decreasing calcium uptake by cells using selected polycations |
| US6090958A (en) * | 1995-03-31 | 2000-07-18 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5866536A (en) * | 1995-03-31 | 1999-02-02 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6001347A (en) | 1995-03-31 | 1999-12-14 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| CN1151836C (en) * | 1995-03-31 | 2004-06-02 | 艾米斯菲尔技术有限公司 | Compound and compositions for delivering active agents |
| US5989539A (en) * | 1995-03-31 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| DE19517430A1 (en) * | 1995-05-12 | 1996-11-14 | Boehringer Mannheim Gmbh | Pharmaceutical dosage form of parathyroid hormone with a two to six hour drug release period |
| US5750147A (en) * | 1995-06-07 | 1998-05-12 | Emisphere Technologies, Inc. | Method of solubilizing and encapsulating itraconazole |
| US5693336A (en) * | 1995-06-07 | 1997-12-02 | Nexstar Pharmaceuticals, Inc. | Blood stable liposomal cyclosporin formulations |
| WO1997010197A1 (en) * | 1995-09-11 | 1997-03-20 | Emisphere Technologies, Inc. | METHOD FOR PREPARING φ-AMINOALKANOIC ACID DERIVATIVES FROM CYCLOALKANONES |
| ATE219374T1 (en) * | 1996-02-01 | 2002-07-15 | Chugai Pharmaceutical Co Ltd | MEDICATIONS FOR THE TREATMENT OR PREVENTION OF THROMBOCYTOPENIA |
| SI9720025A (en) | 1996-03-29 | 1999-08-31 | Emishphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| WO1997047288A1 (en) | 1996-06-14 | 1997-12-18 | Emisphere Technologies, Inc. | Microencapsulated fragrances and method for preparation |
| CA2243643A1 (en) | 1996-11-18 | 1998-05-28 | Susan Haas | Methods and compositions for inducing oral tolerance in mammals |
| US6358504B1 (en) | 1997-02-07 | 2002-03-19 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6060513A (en) * | 1997-02-07 | 2000-05-09 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5990166A (en) * | 1997-02-07 | 1999-11-23 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5773647A (en) * | 1997-02-07 | 1998-06-30 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5804688A (en) * | 1997-02-07 | 1998-09-08 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US6313088B1 (en) | 1997-02-07 | 2001-11-06 | Emisphere Technologies, Inc. | 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents |
| US5863944A (en) * | 1997-04-30 | 1999-01-26 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5962710A (en) * | 1997-05-09 | 1999-10-05 | Emisphere Technologies, Inc. | Method of preparing salicyloylamino acids |
| HUP0103318A2 (en) | 1998-07-27 | 2002-01-28 | Emisphere Technologies Inc. | Process for pulmonary delivery of active agents |
| DE69813908T2 (en) * | 1998-07-28 | 2004-02-05 | Synthes Ag Chur, Chur | USE OF CREATINE SUBSTANCES FOR TREATING BONE AND CARTILAGE CELLS AND TISSUE |
| BR0008590A (en) | 1999-01-08 | 2001-10-30 | Emisphere Tech Inc | Polymeric delivery agent, composition, unit dosage form, method for administering a biologically active agent to an animal requiring the agent, method for preparing a composition; it's composed |
| WO2000050386A1 (en) | 1999-02-26 | 2000-08-31 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| NZ534409A (en) * | 1999-04-05 | 2006-03-31 | Emisphere Tech Inc | Disodium salts, monohydrates, and ethanol solvates for delivering active agents |
| US7129274B1 (en) | 1999-11-05 | 2006-10-31 | Emisphere Technologies Inc. | Phenoxy carboxylic acid compounds and compositions for delivering active agents |
| US7279597B1 (en) | 1999-11-05 | 2007-10-09 | Emisphere Technologies, Inc. | Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| ATE387430T1 (en) | 1999-12-16 | 2008-03-15 | Emisphere Tech Inc | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE INGREDIENTS |
| US20040022838A1 (en) * | 2001-06-20 | 2004-02-05 | Holick Michael F. | Regulation of cell proliferation and differentiation using topically applied peptides |
| EP1349564A2 (en) * | 2000-06-22 | 2003-10-08 | HOLICK, Michael F | Regulation of cellproliferation and differentiation using topically applied peptides |
| AU2001296585A1 (en) * | 2000-10-06 | 2002-04-15 | Michael F. Holick | Regulation of cell proliferation and differentiation using topically applied nucleic acid molecules |
| US20030225300A1 (en) * | 2001-04-19 | 2003-12-04 | Emisphere Technologies Inc. | Compounds and compositions for delivering active agents |
| CN101837120A (en) * | 2001-06-01 | 2010-09-22 | 诺瓦提斯公司 | Method for orally administering parathyroid hormone (PTH) |
| NZ531018A (en) * | 2001-08-17 | 2006-03-31 | Novartis Ag | 5-CNAC as oral delivery agent for parathyroid hormone fragments |
| US20050054557A1 (en) * | 2002-05-09 | 2005-03-10 | Goldberg Michael M. | Compositions for delivering parathyroid hormone and calcitonin |
| KR20060110304A (en) * | 2003-11-25 | 2006-10-24 | 노파르티스 아게 | Biomarkers for the efficacy of calcitonin and parathyroid hormone treatment |
| JP2005209106A (en) * | 2004-01-26 | 2005-08-04 | Nec Corp | Portable communication terminal, received e-mail management method, program and recording medium |
| FR2925333B1 (en) | 2007-12-19 | 2012-04-13 | Farid Bennis | PHARMACEUTICAL COMPOSITIONS COMPRISING AT LEAST ONE PROTEIN ACTIVE INGREDIENT PROTECTS DIGESTIVE ENZYMES |
| BR112012012945A2 (en) | 2009-11-25 | 2020-12-29 | Arisgen Sa | MUCOSAL RELEASE COMPOSITION, ITS PRODUCTION METHOD, PRE-FORMED PEPTIDE COMPLEX, KIT AND USE OF AN ACTIVE PEPTIDE AGENT |
| WO2012130193A1 (en) | 2011-03-31 | 2012-10-04 | Zentiva, K.S. | Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151276A (en) * | 1975-05-12 | 1979-04-24 | Armour Pharmaceutical Company | Method of suppressing gastric acid secretion by the oral administration of calcitonin |
| US4241051A (en) * | 1977-11-04 | 1980-12-23 | Christie Robert B | Calcitonin |
| JPS55153713A (en) * | 1979-05-02 | 1980-11-29 | Kureha Chem Ind Co Ltd | Pharmaceutical preparation of ribosome containing active substance |
| US4342826A (en) * | 1980-02-04 | 1982-08-03 | Collaborative Research, Inc. | Immunoassay products and methods |
| US4459295A (en) * | 1980-03-07 | 1984-07-10 | Interx Research Corporation | Method of increasing oral absorption of glycosidic and related antibiotics |
-
1985
- 1985-08-01 US US06/761,751 patent/US4692433A/en not_active Expired - Fee Related
-
1986
- 1986-07-25 JP JP61504053A patent/JPS63500378A/en active Pending
- 1986-07-25 DE DE8686904723T patent/DE3687899T2/en not_active Expired - Fee Related
- 1986-07-25 AT AT86904723T patent/ATE86102T1/en not_active IP Right Cessation
- 1986-07-25 EP EP86904723A patent/EP0233901B1/en not_active Expired - Lifetime
- 1986-07-25 AU AU61481/86A patent/AU6148186A/en not_active Abandoned
- 1986-07-25 WO PCT/US1986/001553 patent/WO1987000750A1/en active IP Right Grant
- 1986-07-28 CA CA000514753A patent/CA1277595C/en not_active Expired - Fee Related
- 1986-07-29 IL IL79547A patent/IL79547A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0233901A1 (en) | 1987-09-02 |
| WO1987000750A1 (en) | 1987-02-12 |
| JPS63500378A (en) | 1988-02-12 |
| EP0233901B1 (en) | 1993-03-03 |
| ATE86102T1 (en) | 1993-03-15 |
| DE3687899D1 (en) | 1993-04-08 |
| EP0233901A4 (en) | 1988-09-07 |
| AU6148186A (en) | 1987-03-05 |
| IL79547A0 (en) | 1986-10-31 |
| US4692433A (en) | 1987-09-08 |
| DE3687899T2 (en) | 1993-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1277595C (en) | Method and composition for regulating serum calcium levels of mammals | |
| AU599905B2 (en) | Method of increasing bone mass | |
| US4833125A (en) | Method of increasing bone mass | |
| EP0358234B1 (en) | Intranasal calcitonin formulations | |
| US20040018237A1 (en) | Topical drug delivery using phosphatidylcholine | |
| EP0115627A1 (en) | Enhancement of intranasal absorption of calcitonin by formulation with surfactants | |
| KR910004664A (en) | Lung Surfactant Protein Fragments | |
| EP0559751A4 (en) | Treatment for osteoporosis using growth hormone release factor (grf) in combination with parathyroid hormone (pth) | |
| WO1999047160A1 (en) | Stabilized aqueous peptide solutions | |
| JPH0725703B2 (en) | Growth promoting composition | |
| IE881522L (en) | Mixed crystals of insulin | |
| US4241051A (en) | Calcitonin | |
| NL8203315A (en) | PHARMACEUTICAL PREPARATIONS CONTAINING HUMAN INSULIN AND HUMAN C-PEPTIDE. | |
| RU2292219C2 (en) | Pharmaceutical component based on human parathyroid hormone and intranasal pharmaceutical composition containing the same | |
| JPH0873376A (en) | Therapeutic agent for osteoporosis | |
| JPS6360940A (en) | Preventive or remedy for cataract | |
| US20130109631A1 (en) | Agent for growing, restoring and regenerating hair and method of producing a preparation containing the same | |
| DE602005005454T2 (en) | Treatment of inclusion body myositis | |
| JP2003095974A (en) | Composite medicine for safely stimulating osteoplasty | |
| WO2001019359A2 (en) | Medicaments containing pantothenic acid for the treatment of inflammatory joint disease | |
| WO1997003689A1 (en) | Method of treating epilepsy with brain derived neurotrophic factor | |
| Stubbe et al. | Growth response to recombinant human growth hormone of mammalian cell origin in prepubertal growth hormone-deficient children during the first two years of treatment | |
| CN100371018C (en) | Calcitonin composition | |
| GENEVIEVE et al. | Lipolytic effects of insulin in adipocytes isolated from hypophysectomized rats | |
| Hintz et al. | Synthetic hGH causes both increased somatomedin levels and insulin resistance in humans |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |